BenevolentAI SA
AEX:BAI
BenevolentAI SA
Research & Development
BenevolentAI SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BenevolentAI SA
AEX:BAI
|
Research & Development
-£56.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£6.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$13.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$153m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Research & Development
-£15.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.
See Also
What is BenevolentAI SA's Research & Development?
Research & Development
-56.9m
GBP
Based on the financial report for Dec 31, 2023, BenevolentAI SA's Research & Development amounts to -56.9m GBP.
What is BenevolentAI SA's Research & Development growth rate?
Research & Development CAGR 1Y
21%
Over the last year, the Research & Development growth was 21%.
